To wrap up this month’s theme of Olink Explore 1536, here is an example of Olink Explore in action: To better understand the pathology of severe COVID-19 and why SARS-Co-V2 elicits a severe response in some patients, but not in others.
Mar 22, 2021 9:30:00 AM / by Olink posted in Immunological diseases/Immunology, Respiratory disease, Plasma, Clinical research, Publications
To wrap up this month’s theme of Olink Explore 1536, here is an example of Olink Explore in action: To better understand the pathology of severe COVID-19 and why SARS-Co-V2 elicits a severe response in some patients, but not in others.
Mar 1, 2021 9:30:00 AM / by Olink posted in Wider proteomics studies, Plasma, Biomarkers, Multiomics, Basic research, Precision medicine, Olink technology
Advances in genomics have opened the doors to large-scale, high-throughput acquisition of biological data. As a result, our understanding of biology has increased substantially, so much so that this phase in history has been termed the 'DNA revolution'. But what about the workhorses of the body? What more could our proteome reveal? Just as genomics underwent a revolution, proteomics is having its own revolution right now. Introducing Olink Explore 1536, a product created for the screening and discovery of novel protein biomarkers.
Feb 15, 2021 9:30:00 AM / by Olink posted in Wellness, Plasma, Multiomics, Clinical research, Precision medicine, Longitudinal Data
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations. This especially applies to the stability of molecular profiles among healthy individuals over time, as this will clarify what qualifies as a ‘normal range’ of clinical parameters in health and disease research. The following study by Tebani et al. (2020) conducted a longitudinal analysis of the blood profiles from 100 healthy individuals to understand how they varied both between different individuals, and within an individual over time.
Feb 8, 2021 9:30:00 AM / by Olink posted in Oncology, Wellness, Plasma, Biomarkers, Clinical research
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.